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Background and aims: Carotid plaque size and the mean common carotid intima-media thickness
measured in plaque-free areas (PF CC-IMTmean) have been identiﬁed as predictors of vascular events
(VEs), but their complementarity in risk prediction and stratiﬁcation is still unresolved. The aim of this
study was to evaluate the independence of carotid plaque thickness and PF CC-IMTmean in cardiovascular
risk prediction and risk stratiﬁcation.
Methods: The IMPROVE-study is a European cohort (n ¼ 3703), where the thickness of the largest plaque
detected in the whole carotid tree was indexed as cIMTmax. PF CC-IMTmean was also assessed. Hazard
Ratios (HR) comparing the top quartiles of cIMTmax and PF CC-IMTmean versus their respective 1e3
quartiles were calculated using Cox regression.
Results: After a 36.2-month follow-up, there were 215 VEs (125 coronary, 73 cerebral and 17 peripheral).
Both cIMTmax and PF CC-IMTmean were mutually independent predictors of combined-VEs, after
adjustment for center, age, sex, risk factors and pharmacological treatment [HR (95% CI) ¼ 1.98 (1.47,
2.67) and 1.68 (1.23, 2.29), respectively]. Both variables were independent predictors of cerebrovascular
events (ischemic stroke, transient ischemic attack), while only cIMTmax was an independent predictor of
coronary events (myocardial infarction, sudden cardiac death, angina pectoris, angioplasty, coronary
bypass grafting). In reclassiﬁcation analyses, PF CC-IMTmean signiﬁcantly adds to a model including both
Framingham Risk Factors and cIMTmax (Integrated Discrimination Improvement; IDI ¼ 0.009; p ¼ 0.0001)
and vice-versa (IDI ¼ 0.02; p < 0.0001).no, IRCCS, Via Parea 4, 20138
Baldassarre).
Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
M. Amato et al. / Atherosclerosis 263 (2017) 412e419 413Conclusions: cIMTmax and PF CC-IMTmean are independent predictors of VEs, and as such, they should be
used as additive rather than alternative variables in models for cardiovascular risk prediction and
reclassiﬁcation.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The measurement of carotid plaque thickness, rather than the
mean of common carotid intima-media thickness measured in
plaque-free areas (PF CC-IMTmean), is an important yet controversial
issue for cardiovascular risk prediction and/or risk reﬁnement. Both
variables have been associated with vascular events (VEs), inde-
pendently of conventional vascular risk factors (VRFs) [1]. However,
the decision to use one or the other in models for risk prediction or
risk stratiﬁcation is often based on methodological issues such as
accuracy and ease of measurement [2,3], or relative power in risk
prediction [4e8]. Carotid plaque thickness and PF CC-IMTmean are
correlated, yet they differ considerably from a histological point of
view and they can better be considered as distinct phenotypes [9]
describing two different phenomena, being mainly due to athero-
sclerosis [10] and hypertrophy/hyperplasia of smooth muscle cells,
respectively [2]. Several observational studies have focused on
either carotid IMT (cIMT) or plaque, but few studies [5,8,11,12] have
examined whether carotid plaque thickness and PF CC-IMTmean can
be used as additive rather than alternative variables in models for
cardiovascular risk prediction and reclassiﬁcation. With the aim of
gaining further insight into this issue, we evaluated the indepen-
dence of carotid plaque thickness (indexed in terms of cIMTmax i.e.
the maximal carotid IMT detected in the whole carotid tree) and PF
CC-IMTmean, in cardiovascular risk prediction and/or risk reﬁne-
ment in a large, multicenter, prospective cohort study of high-risk
individuals [Carotid IntimaeMedia Thickness (IMT) and
IMTeProgression as Predictors of Vascular Events in a HigheRisk
European Population (acronym: IMPROVE)].
2. Patients and methods
2.1. Subjects
A complete description of the IMPROVE-study design, objec-
tives, sampling strategy and methods for clinical and haemato-
logical evaluation has been reported in the text and Online
Materials of Baldassarre et al. [13,14]. Brieﬂy, a total of 3711 in-
dividuals (age 54e79 years) were recruited, with at least three VRFs
but free of any cardio- or cerebro-VEs prior to enrolment. The
participants were enrolled at 7 centers in 5 European countries:
Finland (Kuopio, 2 centers), France (Paris), Italy (Milan and Peru-
gia), The Netherlands (Groningen) and Sweden (Stockholm).
The occurrence of VEs (myocardial infarction (MI), sudden car-
diac death, angina pectoris, ischemic stroke, transient ischemic
attack, new diagnosis of intermittent claudication, or any surgical
intervention or revascularization of coronary or peripheral arteries)
was assessed at months 15 and 30 by regular visits, and at the end
of follow-up (36 months in average) by phone interview. The
sample size considered for this report is 3703 since the carotid
walls were not properly visualized in 8 subjects.
2.2. Ultrasonographic assessment
The ultrasound procedure in the IMPROVE study has been
described [13,14]. Brieﬂy, 7 identical scanners (Technos System,Esaote, Genoa, Italy) equipped with 5e10 Mhz linear array probes
were used and the images were recorded on sVHS videotapes by
trained sonographers. The cIMT was measured centrally by trained
readers at the ultrasound reading center in Milan. cIMT was
assessed in the entire length of the common carotid, in the carotid
artery bifurcation (1 cm proximal to the ﬂow divider) and in the
internal carotid artery (1 cm immediately distal to the ﬂow divider)
of both left and right carotids. At each of these segments, the mean
and maximal values of IMT were measured on the far wall from
three angles (anterior, lateral and posterior) by means of a speciﬁc
software (M'Ath).
In this study, we also considered the mean of common carotid
IMT measured in plaque-free areas (PF CC-IMTmean), i.e. areas with
a cIMTmax <1 mm. This variable is the average of all plaque-free
mean IMT values obtained from the left and right CC visualized in
their entire length (excluding the 1st cm) with sequential 1 cm-
long probe movements according to the 3 aforementioned scan
angles. The total number of segments averaged for assessing PF CC-
IMTmean ranged from 6 to 24, according to the subject's neck length
and according to the number of segments with cIMTmax 1, which
were excluded from the average calculation. The precision of
cIMTmax has been reported [13]. Details on precision of PF CC-
IMTmean are provided in Supplementary Data.
2.3. Ethical considerations
The Ethics Committees of all participating institutions approved
the IMPROVE study, which complied with the Declaration of Hel-
sinki. Written informed consent was obtained from all subjects.
2.4. Statistical analysis
Cox models were used to estimate crude and adjusted hazard
ratios (HRs) and to compute adjusted Kaplan-Meier survival curves
over 36 months of follow-up. The HRs comparing the top quartiles
of cIMTmax (2.5 mm) and PF CC-IMTmean (0.76 mm) to their
respective 1e3 quartiles were calculated.We decided a priori to use
these cut offs because the ASE consensus statement described PF
CC-IMTmean values  75th percentile as indicative of increased
cardiovascular risk [15]. Regarding plaques, we decided to use
cIMTmax values  75th percentile because most large longitudinal
studies showed that the risk is mainly increased in the top quartiles
or quintiles [16]. As a sensitivity analysis, we also tested models
where cIMTmax and PF CC-IMTmean were included as continuous
variables. Cox models were stratiﬁed for center (Model-1), then
further adjusted for age and sex (Model-2) and then for risk factors
and pharmacological treatment (Model-3). Departure from the
proportional hazard assumption was assessed by the Kolmogorov-
type supremum test computed on 1000 Monte-Carlo simulations.
Area under the ROC curves (AUC), Integrated Discrimination
Improvement (IDI), and Net Reclassiﬁcation Improvement (NRI)
were used for assessing the potential of the PF CC-IMTmean in
improving risk prediction based on cIMTmax and risk factors
included in the Framingham Risk Score (age, sex, total cholesterol,
HDL-cholesterol, systolic blood pressure, diabetes, current smoking
and antihypertensive treatments) and vice-versa. As in our previous
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Risk Score as separated variables in all models, instead of the Fra-
mingham Risk Score, as this algorithm is not speciﬁcally calibrated
for a European population. To assess the impact of cIMTmax and PF
CC-IMTmean on the risk reclassiﬁcation of subjects located in the so
called “gray-zone” of risk prediction, we calculated the clinical NRI,
i.e. the NRI only considering subjects at intermediate-risk
(10% < Framingham Risk Score <20%). Positive and negative pre-
dictive values (PPV and NPV) were also computed.
All statistical tests were two-sided at a level of signiﬁcance of
0.05. All analyseswereperformedusing theSAS statistical packagev.
9.4 (SAS Institute Inc., Cary, NC, USA). Reclassiﬁcation statistics were
assessed with the SAS macros published by Cook and Ridker [17].
3. Results
The baseline characteristics of IMPROVE study participants were
described [13,14]. Brieﬂy, the mean age was 64.2 years and 47.9% of
subjects were males. The participants were followed-up for a me-
dian of 36.2 months (interquartile range: 35.8 to 37.4) and 215
suffered a ﬁrst VE, (incidence: 19.9/1000 person-years). Among
these, 125 had a coronary event [34 had a MI (7 fatal), 3 suffered
sudden cardiac death, 49 experienced symptoms of angina pectoris,
26 underwent angioplasty and 13 coronary bypass grafting]; 73 had
a cerebrovascular event [32 had an ischemic stroke (0 fatal), 41 had
a transient ischemic attack], and 17 had a peripheral VE (4 subjects
underwent revascularization due to peripheral artery disease and
13 had a new diagnosis of intermittent claudication). Eighty par-
ticipants had more than one VE during follow-up, but only the ﬁrst
event was used for the analysis of the primary combined endpoint.
3.1. cIMTmax, PF CC-IMTmean and risk of combined VEs
In Cox regression models with mutual adjustment for cIMTmax
and PF CC-IMTmean, both variables (top quartiles vs. quartiles 1e3)
were signiﬁcantly and independently associated with the risk of
combined-VEs, after stratifying for center (Table 1, Model-1), as
well as with further adjustment for age and sex (Model-2) and for
risk factors and pharmacological treatment (Model-3). These re-
sults were virtually unchanged when cIMTmax and PF CC-IMTmean
were analysed as continuous variables (data not shown). For both
cIMTmax and PF CC-IMTmean, no signiﬁcant departure from the
assumption of proportionality of the hazards was observed
(p ¼ 0.42 and p ¼ 0.46, respectively).
Fig. 1 shows the Kaplan-Meier incidence curves adjusted for
Model-3 covariates and stratiﬁed into four groups according to
cIMTmax and PF CC-IMTmean above or below their respective top
quartiles (2.5 mm and 0.76 mm). The independent effect of the two
variables is clearly shown.
Table 1 also shows that both cIMTmax and PF CC-IMTmean were
independent predictors of cerebrovascular and coronary events in
all models.
Supplemental Table 1 shows the same analyses as Table 1
restricted to “hard clinical events”. While no signiﬁcant associa-
tion with hard coronary events (myocardial infarction, sudden
cardiac death) was detected, the measures of cIMTmax and PF CC-
IMTmean remained signiﬁcantly and independently associated with
hard cerebrovascular events (ischemic strokes), even after adjust-
ing for center, age, sex, Framingham risk factors (FRFs) and phar-
macological treatments (Model 3).
3.2. Incremental predictive value of cIMTmax and PF CC-IMTmean in
reclassiﬁcation analysis
Table 2 shows the reclassiﬁcation statistics for the combinedendpoints. In the ﬁrst line, AUC, NRI and IDI values were obtained
after adding PF CC-IMTmean to a reference model that included FRFs
and cIMTmax. In the second line, AUC, NRI and IDI values were ob-
tained after adding cIMTmax to a referencemodel that included FRFs
and PF CC-IMTmean. cIMTmax appears to improve the classiﬁcation
of cases and controls more effectively than PF CC-IMTmean (NRI:
8.2% vs. 2.4% and IDI: 0.02 vs. 0.009).
Supplemental Tables 2 and 3 and Table 3 show the estimated 10-
year VE risk categories according to FRFs before and after adding
cIMTmax (Supplemental Table 2), PF CC-IMTmean (Supplemental
Table 3) and the combination of the two variables (Table 3). In
Supplemental Table 2, the overall NRI was 10% (p¼ 0.02) and 32% of
subjects at intermediate risk were reclassiﬁed. The addition of PF
CC-IMTmean to FRFs (Supplemental Table 3) resulted in the reclas-
siﬁcation of only 23% of subjects at intermediate risk and the overall
NRI was lower (5.3%) and not statistically signiﬁcant (p ¼ 0.19).
However, when both variables were added (Table 3), the overall NRI
increased to 13.9% (p ¼ 0.003) and the percentage of subjects at
intermediate-risk reclassiﬁed reached approximately 41%. Among
these subjects, 30 cases and 425 non-cases were correctly reclas-
siﬁed, and 6 cases and 239 non-cases were wrongly reclassiﬁed,
yielding a clinical NRI of 45.1%, compared to 29.6% using only
cIMTmax and 27.5% using only PF CC-IMTmean.
PPVs and NPVs for those with a high Framingham risk score
(FRS>20) as well as for top quartile values of PF CC-IMTmean,
cIMTmax or both, assessed considering combined-, coronary- or
cerebrovascular events, are shown in Supplementary Fig. 1. As ex-
pected because of the low incidence of VEs (19.9/1000 person-
years), the PPVs were rather low, (always <21%). However, even
the PPVs of the FRS, the most widely accepted predictor of VEs,
were about half (9.5%, 3.6%, and 5.9% for combined-, coronary- or
cerebrovascular events, respectively) of those obtained with the
combination of PF CC-IMTmean and cIMTmax (18.5%, 7.9%, and 10.9%).
The best PPVs were obtained when all three variables (FRS, PF CC-
IMTmean and cIMTmax) were in the high risk categories.
4. Discussion
This study shows that cIMTmax (an index of the thickest plaque
detected in the whole carotid tree) and PF CC-IMTmean (an index of
the common carotid background thickening) are both independent
predictors of VEs, and that they independently add to risk reclas-
siﬁcation in intermediate risk subjects. It is well known that, taken
by themselves, carotid IMT and the presence/thickness of carotid
plaques are both prognostic predictors of CV events, as reported by
Naqvi and collaborators [1] in a “state-of-the-art” paper that
examined many large cohort studies. Several studies have also
investigated which of these two variables is the strongest predictor
of VEs. Several meta-analyses [6,7] have unequivocally reported
that plaques are more accurate in predicting VEs than CC-IMT. In
addition, studies evaluating whether carotid ultrasonographic
measurements provide additional prognostic information over and
above VRFs have been strongly positive when based on carotid
plaques, and/or on cIMT variables incorporating plaques in their
measurements [5,8,18e23], and weaker or even negative when
based on cIMT measured in plaque-free areas [5,8,16,20,21,23e26].
Hence, it is quite clear and widely accepted that if one must choose
between CC-IMT measured in plaque-free areas or plaques (pres-
ence or thickness) for risk prediction and/or reclassiﬁcation, the
latter is the best choice.
It is important to emphasise that, instead of assessing whether
plaques or PF CC-IMTmean are good and/or equipotent representa-
tions of the atherosclerotic process, the present study focuses on
whether the two ultrasonographic measures represent comple-
mentary prognostic information when used together. To date, the
Table 1
Hazard Ratios (95% CI) and p values of combined, cerebro- and cardio-vascular endpoints comparing top quartiles of both cIMTmax and PF CC-IMTmean vs. quartiles 1e3.
Model-1 Model-2 Model-3
Combined endpoints (n ¼ 215)a
cIMTmax 2.05 (1.55, 2.72); <0.0001 1.88 (1.41, 2.51); <0.0001 1.98 (1.47, 2.67); <0.0001
PF CC-IMTmean 1.89 (1.41, 2.53); <0.0001 1.69 (1.26, 2.27); 0.0005 1.68 (1.23, 2.29); 0.0011
Cerebrovascular endpoints (n ¼ 73) (Ischemic stroke, transient ischemic attack)a
cIMTmax 2.7 (1.67, 4.36); 0.0001 2.55 (1.57, 4.14); 0.0002 2.76 (1.66, 4.6); 0.0001
PF CC-IMTmean 2.25 (1.38, 3.68); 0.0012 2.07 (1.26, 3.4); 0.004 2.13 (1.26, 3.61); 0.005
Coronary endpoints (n ¼ 125) (myocardial infarction, sudden cardiac death, angina pectoris, angioplasty, coronary bypass grafting)a
cIMTmax 1.69 (1.16, 2.47); 0.006 1.51 (1.03, 2.21); 0.036 1.58 (1.06, 2.37); 0.025
PF CC-IMTmean 1.70 (1.15, 2.5); 0.007 1.47 (0.99, 2.17); 0.056 1.49 (0.99, 2.26); 0.057
Model-1: cIMTmax, and PF CC-IMTmean stratiﬁed by center; Model-2: as model-1 plus age and sex; Model-3: as model-2 plus Framingham risk factors, family history of
diabetes, family history of hypertension, pack-years, and pharmacological treatments (statins, beta-blockers, ACE-inhibitors, diuretics and calcium-antagonists).
a Among the 215 combined endpoints, 17 were peripheral VEs (4 subjects underwent revascularization due to peripheral artery disease and 13 had a new diagnosis of
intermittent claudication) and, as such, included neither in the analysis on cerebrovascular endpoints nor in the one on coronary endpoints.
Fig. 1. Framingham risk factors-adjusted Kaplan-Meier incidence curves.
The study population was stratiﬁed according to cIMTmax and PF-CC-IMTmean values above or below their respective 75th percentiles (2.5 and 0.76 mm), respectively. Curves were
computed for the mean value of each covariate used in Table 1, Model-3 (i.e. center, age, sex, Framingham risk factors, family history of diabetes, family history of hypertension,
pack-years and pharmacological treatments (statins, beta-blockers, ACE-inhibitors, diuretics and calcium-antagonists)). IMT, intima-media thickness; PF CC-IMTmean, mean common
carotid IMT measured in plaque-free areas; cIMTmax, measure of the thickest plaque detected in the whole carotid tree.
Table 2
Reclassiﬁcation statistics for PF CC-IMTmean above or below top quartile as compared to classiﬁcation based on Framingham Risk Factors (FRFs) and cIMTmax and vice-versa in
risk models with combined vascular endpoints.
New model Reference model AUC
ref. model
AUC
new model
p
value
NRI
(95% CI)
p
value
IDI
(99% CI)
p
value
FRFs þ cIMTmax þ PF CC-IMTmean FRFs þ cIMTmax 0.661 0.671 0.15 2.4% (3.5, 8.3) 0.42 0.009 (0.003, 0.016) 0.0004
FRFs þ PF CC-IMTmean þ cIMTmax FRFs þ PF CC-IMTmean 0.657 0.671 0.054 8.2% (0.1, 16.3) 0.047 0.02 (0.010, 0.029) <0.0001
When NRI and/or IDI values are positive with a p < 0.01, the new model is better than the reference model, which includes FRFs and cIMTmax and vice-versa. AUC, area under
the ROC curve.
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and reclassiﬁcation has been addressed in only four large pro-
spective cohort studies [5,8,11,12], but with conﬂicting results.
While Plichart [5] and Gardin [12] showed that adding plaques to
cIMT does not result in a statistically signiﬁcant improvement in
risk prediction, Nambi [11] and Gepner [8], in agreement with our
data, found that the prediction of coronary artery disease improves
when cIMT and plaques are combined, compared with eachmeasurement alone.
Some methodological differences in plaque deﬁnition and tar-
gets/modality of carotid IMTmeasurements between our study and
the studies mentioned above should be mentioned. In the study of
Plichart [5] and Gepner [8], plaques were deﬁned as localized echo-
structures for which the wall thickening was at least 50% greater
than surrounding vessel walls. Thus, even a lesion with a thickness
<1 mmwas considered as “plaque” if the thickness of surrounding
Table 3
Risk reclassiﬁcation comparing the extrapolated 10-years risk according to Framingham Risk factors (FRFs) before and after adding both cIMTmax and PF CC-IMTmean in the
prediction of combined vascular events.
10-year risk categories for FRFs 10-year risk categories for FRFs plus cIMTmax plus PF CC-IMTmean
<10% 10e20% >20% N (%) reclassiﬁed
<10%
N ¼ 678 (20%) 556 (82%) 113 (16.7%) 9 (1.3%) 122 (18%)
Observed-risk (95% C.I.) 6.4 (3.2, 10.8) 11.6 (3.2, 25.4) No events
10e20%
N ¼ 1715 (52%) 431 (25.1%) 1015 (59.2%) 269 (15.7%) 700 (41%)
Observed-risk (95% C.I.) 4.5 (1.7, 8.8) 11.1 (7.7, 15) 38 (25.6, 52.7)
>20%
N ¼ 920 (28%) 0 (0%) 322 (35%) 598 (65%) 322 (35%)
Observed-risk (95% C.I.) 24.2 (15.5, 34.7) 36.7 (28.4, 46)
NRI: 13.9%; p ¼ 0.003a
Clinical NRI 45.1%; p < 0.0001b
a NRI: 11.0% (3.1, 18.9); p ¼ 0.007; when statins are added to FRFs.
b Clinical NRI: 26.7% (13.0, 40.3); p ¼ 0.0001; when statins are added to FRFs.
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top quartile of cIMTmax (2.5 mm), so only real atherosclerotic pla-
ques were considered. The other two studies [11,12] evaluated the
utility of adding a measure of plaque burden to cIMT variables
which neither focused strictly on the common carotid artery nor on
plaque-free areas. For example, the cIMT variable used in Gardin's
analysis [12] was the mean of maximum IMT measurements of
several carotid segments (which we deﬁne as IMTmean-max), a var-
iable whose values are directly affected by the presence/absence of
plaques. A similar comparison previously performed in the
IMPROVE cohort [14] produced similar results by showing that the
presence/absence of plaque did not add to reclassiﬁcation when
used on top of ultrasonographic variables which incorporate pla-
ques, yet added to reclassiﬁcation when combined with variables
measured in plaque-free areas. Moreover, our data also show that
the NRI and IDI, provided by the combination of the two variables
used on top of FRFs, are not inferior to those obtained by using
IMTmean-max on top of FRFs (Supplemental Table 4). These data
agree with another study of Nambi et al. [27], who showed that the
evaluation of the carotid artery for plaque presence and measure-
ment of CC-IMT (which is easier and more precise than considering
IMTmean or IMTmean-max in the whole carotid tree) provide a good
alternative to the measurement of cIMT in all segments of the ca-
rotid tree for risk prediction and reclassiﬁcation.
In this study, we, for three reasons, decided a priori to analyse
the complementarity of cIMTmax and PF CC-IMTmean: (1) literature
indications according to published data [15,16], (2) these are the
two variablesmost frequently used in clinical settings, and (3) there
is evidence that, when taken by themselves, measurements of both
variables can be performed in a reproducible way in the clinical
setting [28,29].
Our results distinctly support the concept that these two mea-
sures are complementary in risk prediction. Indeed, at the end of
the follow-up period, FRF-adjusted Kaplan Meier curves (Fig. 1)
shows a substantial increase of event risk in the stratum where
both cIMTmax and PF CC-IMTmean indicate the presence of sub-
clinical disease, compared with the strata where only one of the
two variables were in the top quartile range.
When Cox analyses were restricted to cerebrovascular or coro-
nary endpoints (regardless of whether “hard” or not), the strength
of association between top quartile values and risk of disease was
always greater with cerebrovascular thanwith coronary endpoints,
and this was true even after the analyses were adjusted for center,
pharmacological treatments and FRFs. A potential explanation is
that FRFs are predominantly a tool for prediction of coronary events
[30], whereas cerebrovascular events are related to a broader arrayof causes [31], including embolism from cardiac arrhythmias and/or
valvular disease or hypertension giving rise to small vessel disease
[32]. Another possible explanation is that the presence of athero-
sclerosis in the carotid arteries is both a marker and a cause of
cerebrovascular events, whereas it is merely a marker of coronary
events.
The complementarity of cIMTmax and PF CC-IMTmean is
conﬁrmed by the reclassiﬁcation analysis, particularly in the
intermediate-risk category. With such analysis, several authors
have reported that the improvement of risk stratiﬁcation over
traditional VRFs provided by PF CC-IMTmean alone [5,20,21,24,25] is
less consistent than that provided by plaques alone [5,18e22]. As
well as conﬁrming this ﬁnding (Supplemental Tables 2 and 3), we
show here a substantial improvement of risk stratiﬁcation over
FRFs when both cIMTmax and PF CC-IMTmean are used (Table 3),
with a 3.9% (13.9% minus 10%) increase of NRI and a 15.5% (45.1%
minus 29.6%) increase of clinical NRI when compared with the
model including FRFs and cIMTmax (Supplemental Table 2). Spe-
ciﬁcally, Table 3 shows that the observed risk (38%; 95% CI 25.6,
52.7) of individuals reclassiﬁed to a higher risk category was
actually much higher than the threshold of 20% estimated by FRFs
only, and that the observed risk of individuals reclassiﬁed to a lower
risk category was actually much lower (4.5%; 95% CI 1.7, 8.8) than
the original 10e20% risk estimated by FRFs. By contrast, Table 3
shows that reclassiﬁcation of subjects originally classiﬁed by FRFs
at low or at high risk has to be viewed as inappropriate. For
example, individuals who moved from the high-to intermediate-
risk category had an observed risk of 24.2% (95% CI 15.5, 34.7), i.e. a
risk greater than the threshold of 20%.
Despite this, at least in the intermediate-risk category, the
beneﬁts gained from the improvement in risk classiﬁcation seem to
easily offset the negligible additional costs required for measuring
not only cIMTmax but also CC-IMT in plaque-free areas. Supporting
the results obtained with Cox and reclassiﬁcation analyses, when
the two ultrasonographic variables were both in the top quartile,
the improvements over the best performing single variable were
consistent (þ36%, þ27% and þ40% for composite, cerebrovascular
and coronary-endpoints, respectively). Of note, the PPVs consid-
ering the single ultrasonographic variables were higher than the
PPV of the FRS>20 and the addition of FRS>20 to the test with both
the ultrasonographic variables in the top quartile resulted in a
minor PPV improvement (ranging from 6 to 11%).
Another evidence supporting measurement of PF CC-IMTmean
comes from 1) studies showing that the incidence of stroke [33]
and coronary events [34] is related to cIMT even in the absence of
plaques, 2) case-control studies showing that it is preferable to
M. Amato et al. / Atherosclerosis 263 (2017) 412e419 417combine carotid IMT measurement with plaque assessment rather
than using either measurement alone as screening tests for CHD
[35], and 3) studies showing that the associations between cIMT
and stroke remained signiﬁcant even after adjusting for the pres-
ence of carotid plaques [33]. Moreover, a meta-analysis including
eight relevant studies with cIMT assessment showed that for each
0.10 mm increase in CC-IMT, the estimated incidence of MI in-
creases by 5% (from 12 to 17%) [36], thus suggesting that, even
when measured in plaque-free areas, CC-IMT measurements still
contain additional information for risk prediction regardless of the
presence or absence of atherosclerotic plaques.
The complementary prognostic value of cIMTmax and PF CC-
IMTmean has scientiﬁc support also from a biological/pathophysio-
logical perspective. Carotid IMTmax is a plaque marker [23] and
reﬂects a focal phenomenon mainly related to atherosclerotic
processes such as inﬂammation, oxidation, endothelial dysfunc-
tion, foam cell proliferation and/or thrombosis [10,37]. PF CC-
IMTmean, instead, mainly reﬂects diffuse, non-atherosclerotic,
adaptive changes to increased shear stress mediated by aging [37]
or hypertension [2,38]. In addition, variants in genes involved in
pathways leading to atherosclerosis (e.g. inﬂammation, oxidative
stress, and diabetes) were differentially associated with the two
variables [9,39e43]. Taken together, these pieces of evidences
support the concept that, even if the processes underlying cIMTmax
and PF CC-IMTmean formation may share some common mecha-
nisms for initiation and progression [9,37,44], the two phenotypes
represent biologically distinct aspects - or stages - of atheroscle-
rosis [45]. Their overlap is only partial [37] and, consequently, they
have different, independent and complementary prognostic value
[2,11,19,36,46].
4.1. Strengths and limitations
The study has several strengths. Firstly, this is the ﬁrst report
evaluating the complementarity of cIMTmax and PF CC-IMTmean, in
terms of prediction and reclassiﬁcation, in European subjects at
high risk of cardiovascular disease. The second strength is the tight
control of the methodology for carotid image acquisition and
measurement of ultrasonographic variables. Thirdly, all sonogra-
phers involved in the study were trained and certiﬁed, and all scans
were read blindly in the same reading center. Other advantages are
the large sample size and the tight standardizations of all methods
across all recruitment units. There are also potential limitations:
ﬁrstly, extrapolation of the ﬁndings to the general European pop-
ulation or to patients with fewer than 3 VRFs should be done with
caution. However, the HRs observed are similar to those reported in
other large population studies [1]. Secondly, the low number of VEs
restricted the precision of estimates especially in subgroup ana-
lyses (coronary and cerebrovascular events). Thirdly, a further
stratiﬁcation according to number of plaques (i.e. number of seg-
ments with a cIMTmax>1 mm), as recently suggested [35], was not
considered because of the limited number of VEs, and because
almost all subjects (92.1%) in our “high risk” population have more
than two plaques. However, repeating the analysis shown in Table 1
(Model 3) after including the number of plaques among covariates
did not change the results substantially (data not shown). Fourthly,
the prevalence of subjects treated with statins (40%) may have
affected our reclassiﬁcation analyses. It should be emphasized,
however, that results did not change when statins were added to
the FRFs (see footnotes of Supplemental Tables 2 and 3 and Table 3)
or when the analysis was limited to statin-naïve individuals. In the
latter case, for example, compared with a model including FRFs
only, the IDI values of models including “FRFs þ cIMTmax” or
“FRFs þ PF CC-IMTmean” or their combination (FRFs þ cIMTmax þ PF
CC-IMTmean) were 0.014 (95% CI 0.005, 0.024), p < 0.0001; 0.008(95% CI 0.001, 0.015), p ¼ 0.005; and 0.019 (95% CI 0.008, 0.030),
p < 0.0001, respectively.
We are aware that, based on concerns about quality of cIMT
measurements and on the results of three review/meta-analyses
[47e49], the working group on the 2013 ACC/AHA Cardiovascular
Risk Guidelines [50] decided to advise against measuring cIMT in
routine clinical practice for risk assessment for a ﬁrst cardiovascular
event in the general population. Nonetheless, our study has shown
that cIMTmax and PF CC-IMTmean contribute signiﬁcant and inde-
pendent incremental prediction beyond FRFs alone, and that it is
better to combine than use either measure alone.4.2. Conclusions
Bearing in mind the almost negligible costs required for adding
measurements of PF CC-IMTmean in scans devoted to cIMTmax
measurements, we conclude that a risk stratiﬁcation strategy based
on the concomitantmeasurement of cIMTmax and PF CC-IMTmean, as
an adjunct to FRFs, is a rational approach for better identifying
subjects who need to be treated with pharmacological and/or
lifestyle intervention (diet, smoking cessation etc.).Conﬂict of interest
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